Advocacy and Outreach by NPA Leadership
- NPA letter of thanks to FDA re e-cigarette regulation (May 2016)
- Dr. Andrew Kolodny’s testimony before Congress: Opioids and the FDA” (February 2016)
- Health Affairs Blog, “The 21st Century Cures Act: More Homework To Do” (September 2015)
- Article by John H. Powers III, MD in Annals of Internal Medicine, “Regulating Antibiotics in an Era of Resistance: The Historical Basis and Continued Need for Adequate and Well-Controlled Investigations” (July 2015)
- HealthNewsReview.org post, “Criticism of NEJM’s defense of industry-physician relations” (May 2015)
- Dr. Richard Bruno’s FDA Testimony: Antibiotic Ceftazadime-Avibactam (CAZ-AVI) (December 2014)
- Testimony Before AIDAC by John Fratti, Dr. Susan Molchan, Joseph Brodine, and Reshma Ramachandran (December 2014)
- Testimony before the FDA Anti-Infective Drugs Advisory Committee by Dr. Nida Degesys (March 2014)
- Washington Post Letter to the Editor, “Focus on the roots of antibiotic resistance, not the hype,” by Dr. Lisa Plymate (October 2013)
- Testimony before FDA Advisory Board by Dr. Lisa Plymate (October 2013)
- Brookings Institute Presentation by Dr. Cheryl Bettigole (August 2013)
- Testimony on Calcitonin given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)
- Testimony on Gabapentin given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)
- Testimony on Paroxetine given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)
Get NPA Email Updates
Read our Report
Responsible Prescribing
Limiting Pharma's Influence
The NPA encourages all physicians to join our Unbranded Doctor network — prescribers committed to reducing the influence of pharmaceutical marketing on our profession.